IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9242969 B1

PDFFull Text
Date of Patent:
Jan. 26, 2016

Filed:

Mar. 11, 2014

Biaryl amide compounds as kinase inhibitors

Applicant:

Novartis Ag, Basel, CH;

Inventors:

Paul A. Barsanti, Pleasant Hill, CA (US);

Matthew Burger, Albany, CA (US);

Yan Lou, Pleasanton, CA (US);

Gisele Nishiguchi, Albany, CA (US);

Valery Polyakov, Moraga, CA (US);

Savithri Ramurthy, Walnut Creek, CA (US);

Alice Rico, Castro Valley, CA (US);

Lina Setti, Fremont, CA (US);

Aaron Smith, Fremont, CA (US);

Benjamin Taft, Oakland, CA (US);

Huw Tanner, Alameda, CA (US);

Alan DiPesa, Roslindale, MA (US);

Naeem Yusuff, Cambridge, MA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:

Scott W. Reid

Primary Examiner:

Deepak Rao

Int. Cl.
CPC ...
C07D 401/04 (2006.01); C07D 403/04 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); C07D 413/04 (2006.01); A61K 45/06 (2006.01); C07D 213/74 (2006.01); C07D 237/20 (2006.01); C07D 239/42 (2006.01); C07D 239/47 (2006.01); C07D 239/48 (2006.01); C07D 277/42 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 493/10 (2006.01); C07D 403/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 213/75 (2006.01); C07D 233/88 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 241/20 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 263/58 (2006.01); C07D 491/107 (2006.01); C07D 493/04 (2006.01); C07D 495/04 (2006.01); C07D 498/08 (2006.01); C07D 513/04 (2006.01);
U.S. Cl.
CPC ...
C07D 413/04 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); C07D 213/74 (2013.01); C07D 213/75 (2013.01); C07D 233/88 (2013.01); C07D 237/20 (2013.01); C07D 239/42 (2013.01); C07D 239/47 (2013.01); C07D 239/48 (2013.01); C07D 241/20 (2013.01); C07D 263/58 (2013.01); C07D 277/42 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01); C07D 493/04 (2013.01); C07D 493/10 (2013.01); C07D 495/04 (2013.01); C07D 498/08 (2013.01); C07D 513/04 (2013.01);
Abstract

The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Find Patent Forward Citations

Loading…